Peer-reviewed veterinary case report
Butterbur extract safety and effects in dogs with oral melanoma
By Noguchi, Shunsuke et al.·Published in BMC veterinary research·2026·School of Veterinary Science, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical impact of butterbur shoot extract in dogs with oral melanoma: a combined phase 1 and 2 clinical trial.
- Species:
- dog
Plain-English summary
A group of dogs with oral melanoma, a serious type of cancer, were treated with a new extract from Japanese butterbur shoots after undergoing surgery or radiation therapy. The study found that the extract was safe at a dose of 200 mg/kg and led to a significant increase in overall survival for the dogs, although it did not affect how long they lived without the disease progressing. Some mild side effects like elevated liver enzymes and diarrhea were noted, but no serious toxicities occurred. This promising treatment could help improve outcomes for dogs battling this aggressive cancer.
People also search for: dog oral melanoma treatment · butterbur extract for dogs · canine cancer survival rates
Abstract
BACKGROUND: Oral melanoma is one of the most devastating cancers in dogs. We previously developed a novel agent extracted from Japanese butterbur shoots and its petasin derivatives demonstrated anti-proliferative activity in canine oral melanoma cells. The aim of this study was to evaluate the safety and clinical efficacy of the butterbur shoot extract (BSE) in dogs with oral melanoma as a combined phase 1 and 2 study. RESULTS: All enrolled dogs underwent radiation therapy or surgery as local therapy before BSE administration. We enrolled nine dogs in the phase 1 study, and BSE was orally administered at doses escalating from 50 to 200 mg/kg. Grade 1 alanine aminotransferase elevation and diarrhoea were observed in each dog. We determined that 200 mg/kg BSE was safe to administer. We subsequently administered it to sixteen dogs with stage 3 oral melanoma in the phase 2 study. Their progression-free survival and overall survival were compared with those of the historical controls, and adverse events were assessed. BSE administration significantly extended overall survival but did not prolong progression-free survival. No dose-limiting toxicities were observed. CONCLUSIONS: These results indicate that 200 mg/kg of BSE is safe to administer and may improve the outcome of canine oral melanoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-026-05326-w.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41721401/